Home NLENAAAA

Pre-announcement STW Take-off grant (40k),

Technology Foundation STW invites applications for its take-off feasibility studies grants. These aim to support feasibility studies to help speed up the commercialisation of innovative knowledge. Innovation focused on products, processes, care or services from every academic discipline is eligible for funding. The deadline is 28 March 2016.

Take-off grant

The program Take-off is aimed at facilitating and encouraging business and entrepreneurship from the Dutch universities and research institutes recognized by NWO. This involves the creation of innovative new businesses following knowledge development and use by researchers at these universities.
Take-off program has two components: feasibility studies and early phase projects. Both components are explained in the call for proposals (see link below). Take-off is set for the years 2014-2018 and has two rounds each year.

Earlier awarded Take-off grants

AMC project on the commercial development of VHH antibodies against BMP4 receives a € 40K STW Valorisation grant
Within AMC’s Department of Gastroenterology, Prof. Dr. Sheila Krishnadath and her team have been working for more than 15 years on translational research in the field of esophageal cancer. One major focus has been on BMPs (bone morphogenetic proteins) in pathways leading to cancer. Recently she and her postdoc, Dr. Silvia Calpe,  developed single low molecular weight (single domain)antibodies against BMP4. These antibodies were found to have high affinity and specificity for binding  BMPs and to inhibit specific processes believed to be involved in the development of cancer and metastasis. For the further development of these antibodies, Prof. Krishnadath applied for an STW Take-off 1 grant of € 40,000, which she was awarded last week. With the grant she intends to test the antibodies in mouse models for different gastrointestinal cancers as a first next step towards their development as a new anti-cancer drug that is likely to enhance the effect of chemotherapy and potentially has a positive effect on metastasis as well.

AMC project on the commercial development of biological pacemakers awarded a € 40K STW Valorisation grant
Conventional pacemakers have several drawbacks, e.g. the need for replacement when the battery wears out (requiring replacement surgery) and the fact that electronic pacemakers are not able to provide an adequate rate-response during exercise. Solutions to these problems may be provided by the development of biological pacemakers. Such pacemakers are fabricated from engineered stem cells or gene therapies that use pacemaker function-related genes. Within AMC’s Department of Cardiology, the group of Dr. Hanno Tan and Dr. Geert Boink is developing such biological pacemakers. For further development of these biological approaches, Dr. Boink applied for an STW Take-off 1 grant of € 40,000, which was awarded last week. With this grant he intends to construct new viral vectors to conduct final pre-clinical testing. These studies mark an important step towards the development of clinically applicable biological pacemakers that have the potential to improve quality of life in the majority of pacemaker patients.

Read more about the Take-off grant.